ImmunXperts
0552.755.587 · rovalta.com · 23/09/2026
ACTIVE
ImmunXperts
Financial year 2024 · closed on 31/12/2024
Net result
-3 M €
-1017.7% YoY
Gross margin
393,3 k €
-84.7% YoY
Equity
-1,6 M €
-214.1% YoY
Workforce
26,7 ETP
+8.5% YoY
Overview
What does ImmunXperts do?
ImmunXperts is a Public limited company incorporated in 2014. Its main activity is: Research and experimental development on natural sciences and engineering. Its registered office is in Charleroi. It employs on average 26,7 ETP workers (FTE).
Legal situation
● Normal situation
BCE/KBO no. / VAT
BE 0552.755.587
Incorporation
16/05/2014
Legal form
Public limited company
Registered office
Rue Clément Ader 10
6041 Charleroi · WallonieSee on map
6041 Charleroi · WallonieSee on map
Contributed capital
830 878,94 €
Latest accounts
31/12/2024
Average workforce
26,7 ETP
Activities (NACE)
Joint committees (1)
- 207
Available with a Rovalta subscriptionTry for 7 days
Financials
Trend over 10 financial years
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||||||||||
| Gross margin | 393,3 k € | -84.7% | 2,6 M € | -6.8% | 2,7 M € | +13.3% | 2,4 M € | +64.6% | 1,5 M € | +40.5% | 1 M € | +32.7% | 790,5 k € | +2.5% | 770,9 k € | +973% | 71,8 k € | +118% | -394,6 k € |
| EBITDA | -1,8 M € | -764% | 269,6 k € | -73.4% | 1 M € | +54.2% | 658,1 k € | +59.2% | 413,5 k € | +0.9% | 409,6 k € | +15.7% | 354 k € | -23.1% | 460,5 k € | +696% | -77,2 k € | +86.2% | -557,6 k € |
| Operating result | -2,7 M € | -769% | -306,7 k € | -191% | 336,9 k € | +1089% | -34,1 k € | +80.8% | -177,8 k € | -33.4% | -133,3 k € | -286% | -34,5 k € | -119% | 181,3 k € | +198% | -185,8 k € | +70.4% | -628,3 k € |
| Net result | -3 M € | -1018% | -266,3 k € | -158% | 458,5 k € | +92.6% | 238 k € | +6259% | -3,9 k € | -139% | 9,8 k € | -81.1% | 52 k € | -72.4% | 188,5 k € | +194% | -200,5 k € | +68.8% | -641,6 k € |
| Balance sheet | |||||||||||||||||||
| Equity | -1,6 M € | -214% | 1,4 M € | -20.5% | 1,8 M € | +21.5% | 1,5 M € | +0.3% | 1,5 M € | +9.0% | 1,3 M € | +15.8% | 1,1 M € | +35.9% | 845,2 k € | +48.8% | 568,1 k € | +2279% | 23,9 k € |
| Total assets | 9,6 M € | -11.7% | 10,8 M € | +62.8% | 6,7 M € | +26.0% | 5,3 M € | +73.3% | 3 M € | +14.4% | 2,7 M € | -2.4% | 2,7 M € | +28.2% | 2,1 M € | +102% | 1,1 M € | +73.9% | 606,1 k € |
| Cash | 1,5 M € | -15.3% | 1,8 M € | +195% | 605,2 k € | +7.4% | 563,6 k € | +82.3% | 309,2 k € | -15.4% | 365,6 k € | +15.2% | 317,4 k € | -54.3% | 694,2 k € | +49.1% | 465,7 k € | +94.9% | 239 k € |
| Debts | 11 M € | +16.6% | 9,4 M € | +149% | 3,8 M € | +0.6% | 3,8 M € | +199% | 1,3 M € | +13.5% | 1,1 M € | -6.0% | 1,2 M € | -7.6% | 1,3 M € | +165% | 481,7 k € | -16.7% | 578,6 k € |
| Other | |||||||||||||||||||
| Workforce | 26,7 ETP | +8.5% | 24,6 ETP | +11.8% | 22,0 ETP | +20.2% | 18,3 ETP | +38.6% | 13,2 ETP | +32.0% | 10,0 ETP | +35.1% | 7,4 ETP | – | – | 1,9 ETP | |||
Governance
Board of directors
Seen on filing of 31/12/2024 · 3 active · 38 ended
Active mandates
Emmanuel Vanderhaegen
ActiveClément Vanthournhout
ActiveSofie Pattyn
ActiveEnded mandates
Clément Vanthournhout
EndedFrank Swaelens
EndedSofie Pattyn
EndedVahé Kalusyan
EndedAt this address
Other companies at this address
| Company | CBE no. |
|---|---|
2 Bridge WL● Active | 1003.906.745 |
3D Fibroscreen● Active | 1022.772.354 |
AdipoPharma Belgique● Active | 1008.146.338 |
ATRYON BELGIUM● Active | 0751.698.530 |
| 0479.250.670 | |
ConvEyXo● Active | 0725.874.259 |
CONVEYXO GROUP● Active | 1016.957.797 |
ELKEDONIA BELGIUM● Active | 1021.635.177 |
ENDO TOOLS THERAPEUTICS● Active | 0807.570.233 |
Enodia Therapeutics Belgium● Active | 1039.324.811 |
EU BIOTECH CAMPUS● Active | 0776.668.706 |
Exo-Harvest● Active | 0803.425.264 |
Hemastatx● Active | 1019.406.058 |
Immunofusion● Active | 0804.563.629 |
INCHINN THERAPEUTICS● Active | 0799.914.755 |
INSTAR BELGIQUE● Active | 1039.395.085 |
KOKUMA● Active | 0799.078.377 |
LYS MEDICAL● Active | 0688.626.061 |
MILEUTIS● Active | 1011.400.984 |
Nexelis Europe● Active | 0744.498.061 |
Financials
Annual accounts
Full financial information
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|
| Type of account | Abridged model | Abridged model | Abridged model | Abridged model | Abridged model | Abridged model |
| Start of the financial year | 01/01/2024 | 01/01/2023 | 01/01/2022 | 01/01/2021 | 01/01/2020 | 01/01/2019 |
| Closing of the financial year | 31/12/2024 | 31/12/2023 | 31/12/2022 | 31/12/2021 | 31/12/2020 | 31/12/2019 |
| Length of the financial year | 12 months | 12 months | 12 months | 12 months | 12 months | 12 months |
| Filing date | 08/07/2025 | 28/06/2024 | 16/08/2023 | 22/06/2022 | 30/08/2021 | 22/07/2020 |
| General meeting | 30/06/2025 | 05/06/2024 | 30/06/2023 | 07/06/2022 | 25/08/2021 | 30/06/2020 |
| Currency of the financial year | EUR | EUR | EUR | EUR | EUR | EUR |
| NBB quality label | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls |
Ratios
Financial ratios
Looking for more information about this company?
Try for 7 daysFilings
Annual accounts filings
10 filings with the NBB
| Model | Closing | General meeting | Filed | Language | Document |
|---|---|---|---|---|---|
| Abridged model | 31/12/2024 | 30/06/2025 | 08/07/2025 | French | |
| Abridged model | 31/12/2023 | 05/06/2024 | 28/06/2024 | French | |
| Abridged model | 31/12/2022 | 30/06/2023 | 16/08/2023 | French | |
| Abridged model | 31/12/2021 | 07/06/2022 | 22/06/2022 | French | |
| Abridged model | 31/12/2020 | 25/08/2021 | 30/08/2021 | French | |
| Abridged model | 31/12/2019 | 30/06/2020 | 22/07/2020 | French | |
| Abridged model | 31/12/2018 | 05/06/2019 | 24/06/2019 | French | |
| Micro model | 31/12/2017 | 05/06/2018 | 20/06/2018 | French | |
| Micro model | 31/12/2016 | 05/06/2017 | 30/06/2017 | French | |
| Abridged model | 31/12/2015 | 06/06/2016 | 28/06/2016 | French |
Valuation
Estimate
Indicative valuation
The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.
Disclaimer
Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.
Directors & structure
Governance
Board of directors
Seen on filing of 31/12/2024 · 3 active · 38 ended
Active mandates
Emmanuel Vanderhaegen
ActiveClément Vanthournhout
ActiveSofie Pattyn
ActiveEnded mandates
Clément Vanthournhout
EndedFrank Swaelens
EndedSofie Pattyn
EndedVahé Kalusyan
EndedShareholders
Ownership and network
Looking for more information about this company?
Try for 7 daysPublications
Belgian Official Gazette
Belgian Official Gazette publications
- Mandates08/01/2026DEMISSIONS, NOMINATIONS
- Registered office02/02/2024SIEGE SOCIAL
- Mandates04/05/2023DEMISSIONS, NOMINATIONS
- Mandates14/02/2023DEMISSIONS, NOMINATIONS
- Mandates31/05/2022DEMISSIONS, NOMINATIONS
- Mandates14/04/2021DEMISSIONS, NOMINATIONS
- Mandates16/04/2020DEMISSIONS, NOMINATIONS - STATUTS (TRADUCTION, COORDINATION, AUTRES MODIFICATIONS, )
- Capital / shares26/03/2020CAPITAL, ACTIONS
Source: Belgian Official Gazette
Similar companies
Competition
Similar companies
A company's peers, by sector and size, are included in the Business plan.
See the Business planTimeline
Timeline
- 2024Annual accounts 2024-3 M €↓
- 2023Annual accounts 2023-266,3 k €↓
- 2022Annual accounts 2022458,5 k €↑
- 2021Annual accounts 2021238 k €↑
- 2020Annual accounts 2020-3,9 k €↓
- 2019Annual accounts 20199,8 k €↓
- 2018Annual accounts 201852 k €↓
- 2017Annual accounts 2017188,5 k €↑
- 2016Annual accounts 2016-200,5 k €↑
- 2015Annual accounts 2015-641,6 k €
- 16/05/2014IncorporationPublic limited company